Anti-Counterfeit and Customer Engagement solutions provider YPB Group Ltd (ASX:YPB) has signed its first cannabis industry client in the USA and the second client since the launch of the partnership with Namaste Technologies (CVE:N).
YPB Group Ltd (ASX:YPB) provides the Company's Review of Q1 2018 Activities.
Anti-Counterfeit and Customer Engagement solutions provider YPB Group Ltd (ASX:YPB) has signed its first client under its partnership with Namaste Technologies (CVE:N), leading Chinese vaporizer manufacturer Kingtons.
Oventus Medical Ltd (ASX:OVN) announces its Appendix 4C Report for the three-month period ending 30 June 2018 (Q4 FY2018) and is pleased to provide a review of progress made during the quarter.
Anti-Counterfeit and Customer Engagement solutions company YPB Group Ltd (ASX:YPB) has signed a three year Master Supply Agreement with Namaste Technologies Inc (CVE:N) whereby the two Companies will exclusively work together leveraging Namaste's suppliers across the global cannabis industry and particularly those accessing Namaste's large and growing e-commerce customer base.
Oventus Medical Ltd (ASX:OVN) is pleased to provide a copy of its latest newsletter for investors.
Oventus Medical Ltd (ASX:OVN) is pleased to attach a copy of the presentation that Founder and Clinical Director, Dr Chris Hart will deliver to investors this morning at the Thorney Sydney Investment Forum.
Oventus Medical Ltd (ASX:OVN) is pleased to announce positive interim data being presented today in a lecture at Macquarie University on a group of hard-to-treat obstructive sleep apnoea patients, who were studied in a sub-group as part of the ongoing "NeuRA Sydney study".
MMJ PhytoTech Ltd (ASX:MMJ) announces the Company's portfolio divestments.
Oventus Medical Ltd (ASX:OVN) is pleased to announce the results of the OVEN-003 clinical trial study being conducted in Brisbane by the company, a randomised controlled clinical trial examining the treatment outcomes of oral appliance therapy with and without 'Oventus Airway Technology'.
